Acamprosate
Acamprosate helps adults with alcohol use disorder maintain abstinence after they have stopped drinking. It works alongside counseling, recovery support, and an agreed treatment plan.
The education library
Search medication and brand names, open a guide, or keep a printer-friendly copy.
171 guides
Acamprosate helps adults with alcohol use disorder maintain abstinence after they have stopped drinking. It works alongside counseling, recovery support, and an agreed treatment plan.
Agomelatine treats major depression in adults in countries where it is approved. This guide describes the UK oral formulation; it is not a routine U.S. prescription option.
Alprazolam is a benzodiazepine prescribed for anxiety and panic disorder. Immediate-release and extended-release formulations have different schedules; XR is used for panic disorder.
Amantadine treats certain movement symptoms. Immediate-release formulations may be used for Parkinson disease and medication-induced stiffness, tremor, or slowed movement. Extended-release formulations have specific Parkinson-related indications. Confirm the purpose of your prescription.
Oral amisulpride is prescribed for schizophrenia in countries where that formulation is approved. It can reduce hallucinations, suspicious thoughts, and other symptoms.
Amitriptyline treats depression. Providers also use it off-label for conditions such as nerve pain and migraine prevention. The dose and goals may differ from those used for depression.
Amoxapine treats depression, including depression accompanied by anxiety or psychotic symptoms. It is not a general substitute for schizophrenia treatment.
Aripiprazole is used for schizophrenia, bipolar I disorder, and as an add-on treatment for major depression. Other approved uses and ages depend on the formulation.
Armodafinil improves wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea, or shift-work disorder.
Sublingual asenapine is used for schizophrenia and manic or mixed episodes of bipolar I disorder. The skin patch is approved for schizophrenia in adults. It is not a treatment specifically approved for bipolar depression.
Atomoxetine is a nonstimulant treatment for ADHD. It is taken regularly to improve attention and reduce impulsivity or hyperactivity, rather than as an occasional dose for a demanding day.
Benztropine treats certain movement symptoms caused by antipsychotic medicines, such as stiffness, tremor, or acute muscle spasms. It is also used for some symptoms of Parkinson disease. It does not treat tardive dyskinesia and can make that condition worse.
Blonanserin treats schizophrenia in Japan and certain other countries. This guide primarily describes oral treatment. Local approval, available formulations, and driving instructions differ from U.S. prescribing.
Bremelanotide treats acquired, generalized hypoactive sexual desire disorder in premenopausal women when low desire causes distress and is not explained by another condition, medication, or relationship issue. It is not approved to enhance sexual performance or for men or postmenopausal women.
Brexanolone was an IV treatment for postpartum depression. U.S. approval of Zulresso was withdrawn effective April 14, 2025, at the manufacturer’s request after it stopped marketing the medication.
Brexpiprazole treats schizophrenia, is added to an antidepressant for major depression, and treats agitation associated with Alzheimer dementia. For Alzheimer-related agitation, it is scheduled treatment—not an as-needed calming dose.
Buprenorphine treats opioid use disorder by reducing withdrawal and cravings. Continued treatment helps reduce overdose risk. This sheet focuses on opioid use disorder.
Bupropion treats depression. Certain XL formulations help prevent seasonal depression, and SR is used to help adults stop smoking.
Buspirone treats ongoing anxiety, particularly generalized anxiety disorder. Providers sometimes use it off-label alongside an antidepressant. It is not a rescue medication for a sudden panic attack.
Caprylidene was marketed as a medical food for dietary support in Alzheimer disease. It is not an FDA-approved medication for dementia, and a dependable benefit for memory or daily functioning has not been established.
Carbamazepine treats certain seizures and trigeminal neuralgia. Equetro is approved for acute manic or mixed episodes of bipolar I disorder; other psychiatric uses or formulations may be off-label.
Cariprazine treats schizophrenia, manic or mixed episodes and depressive episodes of bipolar I disorder, and is added to an antidepressant for major depression. Doses differ by indication.
Centanafadine is a treatment for attention-deficit/hyperactivity disorder (ADHD). This guide addresses adult use. Treatment aims to improve attention, organization, and impulse control in daily life.
Chlordiazepoxide is used for short-term anxiety treatment and medically managed alcohol withdrawal. Alcohol withdrawal can be dangerous; this medication should be part of a supervised plan rather than a self-directed detox.
Chlorpromazine treats psychotic disorders and manic symptoms. It also has uses outside psychiatry, including certain severe nausea and persistent hiccups. Your dose and treatment goals depend on the reason it was prescribed.
Citalopram treats major depression. It is also prescribed off-label for some anxiety disorders or OCD. Off-label use means the FDA has not approved that specific indication.
Clomipramine is approved for OCD. Providers may also use it off-label for depression or certain anxiety conditions. For OCD, medication is often paired with exposure and response prevention therapy.
Clonazepam treats panic disorder and certain seizure disorders. Some other anxiety uses are off-label. A seizure-treatment schedule should not be changed to occasional use.
Clonidine treats high blood pressure. Certain extended-release formulations are approved for ADHD in children and adolescents; adult psychiatric use for ADHD, hyperarousal, tics, or sleep symptoms is generally off-label.
Clorazepate treats anxiety and alcohol-withdrawal symptoms and is used with other medication for certain seizures. The dosing plan differs for each purpose.
Clozapine treats schizophrenia that has not responded adequately to other antipsychotics. It also reduces recurrent suicidal behavior in people with schizophrenia or schizoaffective disorder when that risk is substantial.
In France, cyamemazine is used for psychosis and selected short-term anxiety or antidepressant add-on treatment. The French anxiety indication is limited to four weeks; certain depression add-on use is limited to the initial four to six weeks.
Daridorexant treats adult insomnia involving difficulty falling asleep, staying asleep, or both.
Desipramine treats depression. Providers sometimes prescribe it off-label for nerve pain or ADHD when other options are not suitable.
Desvenlafaxine treats major depression. It is sometimes used off-label for menopausal hot flashes; that use has a different treatment goal.
Deutetrabenazine treats tardive dyskinesia in adults and chorea associated with Huntington disease. It reduces unwanted movements but does not cure the underlying condition.
Igalmi treats acute agitation associated with schizophrenia or bipolar I or II disorder in adults under a healthcare provider’s supervision. IV dexmedetomidine is used for sedation in monitored medical settings and has a different regimen.
Dexmethylphenidate treats ADHD. It can improve attention, follow-through, and impulse control when the dose and duration match your needs.
Dextroamphetamine is prescribed for ADHD; certain oral formulations are also used for narcolepsy. Approved ages and uses vary by formulation.
A short-term cough suppressant. The right bottle—and the right dose—make a difference.
Auvelity treats major depression in adults and agitation associated with Alzheimer dementia. It is scheduled treatment, not an as-needed calming medicine. It does not cure dementia.
Nuedexta treats pseudobulbar affect: sudden episodes of laughing or crying that are difficult to control and out of proportion to the situation in certain neurologic conditions. This is different from depression or ordinary mood changes.
Diazepam is used for anxiety, muscle spasms, alcohol withdrawal, and certain seizures. Nasal and rectal rescue formulations have specific seizure-emergency instructions; they are different from a routine oral prescription.
Diphenhydramine treats allergy symptoms and is included in some over-the-counter sleep aids. It is generally a poor choice for ongoing insomnia because of next-day effects, tolerance to sedation, and anticholinergic risks.
Disulfiram supports an alcohol-abstinence plan by causing an unpleasant and potentially dangerous reaction if alcohol is consumed. It does not directly treat withdrawal or reliably reduce cravings. It must be taken with your full knowledge and agreement.
Donepezil treats symptoms of Alzheimer dementia. It may help cognition or daily functioning for a time, but it does not cure Alzheimer disease or stop its progression.
Dosulepin, also called dothiepin, is used for depression in certain countries. Because of toxicity and overdose risk, UK guidance restricts its role; initiation should be managed by an appropriate specialist when alternatives are unsuitable.
Low-dose doxepin treats insomnia involving difficulty staying asleep. Much higher oral doses treat depression or anxiety. These regimens have different instructions and side-effect burdens. Topical doxepin for itching is a separate formulation.
Duloxetine treats depression, generalized anxiety disorder, and certain pain conditions, including diabetic nerve pain, fibromyalgia, and chronic musculoskeletal pain. Your treatment goal may involve mood, pain, or both.
Escitalopram treats major depression and generalized anxiety disorder. Providers also use it off-label for some other anxiety conditions, OCD, or related symptoms.
Spravato treats treatment-resistant depression in adults, either alone or with an oral antidepressant. It is also used with an oral antidepressant for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior.
This benzodiazepine is used for short-term treatment of significant insomnia where approved. Ongoing insomnia needs assessment and a review of alternatives such as CBT-I.
Eszopiclone treats difficulty falling asleep or staying asleep. The duration and frequency of use should be reviewed with your provider rather than assumed to be the same for everyone.
Ethyl loflazepate is used in Japan and some other countries for anxiety-related symptoms in specified conditions. It is not approved for medical use in the United States and is not a stand-alone treatment for major depression.
Flibanserin treats acquired, generalized hypoactive sexual desire disorder in women younger than 65 when low desire causes distress and is not explained by another condition, medication, or relationship problem. Current U.S. labeling includes eligible premenopausal and postmenopausal women.
Flumazenil reverses some effects of benzodiazepines after procedures or in selected overdose situations. It is administered by clinicians with monitoring and emergency support. It is not a home rescue medication.
This benzodiazepine is used for short-term treatment of significant insomnia where approved. Ongoing insomnia needs assessment and a review of alternatives such as CBT-I.
Fluoxetine treats depression, OCD, panic disorder, and bulimia. Certain formulations are used for premenstrual dysphoric disorder. A separate combination with olanzapine has additional indications and its own risks.
UK Depixol tablets and long-acting injections treat schizophrenia and other psychoses. Low-dose Fluanxol tablets have a separate depression indication and regimen. Do not assume that the low-dose and antipsychotic regimens are interchangeable.
Fluphenazine treats psychotic disorders such as schizophrenia. Continued treatment can help prevent symptoms from returning when it is effective and tolerated.
This benzodiazepine is used for short-term treatment of significant insomnia where approved. Ongoing insomnia needs assessment and a review of alternatives such as CBT-I.
Current U.S. formulations are labeled for OCD. Providers also use fluvoxamine off-label for depression and certain anxiety disorders. For OCD, medication is often combined with exposure and response prevention therapy.
Gabapentin treats certain seizures and postherpetic nerve pain. Providers also use it off-label for some other pain or anxiety-related conditions. Evidence differs by condition; it is not an established bipolar mood stabilizer.
Galantamine treats symptoms of mild to moderate Alzheimer dementia. It may support cognition or daily functioning for a time, but does not cure the disease or stop its progression.
Gepirone treats major depressive disorder in adults. The goal is improvement in mood, interest, and daily functioning. It is taken regularly, rather than only on difficult days.
Extended-release guanfacine is used for ADHD, alone or with a stimulant; the U.S. evidence and labeling primarily concern children and adolescents. Adult ADHD treatment is generally off-label. Immediate-release guanfacine is approved for high blood pressure.
Haloperidol treats psychotic disorders and is used in selected situations for severe agitation or tics. The reason for use determines whether treatment is short-term or ongoing.
Hydroxyzine is an antihistamine used for anxiety and itching. It is sometimes prescribed off-label for sleep. It can help short-term symptoms, but ongoing anxiety or insomnia still needs a broader treatment plan.
Iloperidone treats schizophrenia and acute manic or mixed episodes of bipolar I disorder in adults. It is not specifically approved for bipolar depression.
Imipramine treats depression. Adult off-label uses include certain anxiety or pain conditions. Pediatric bedwetting treatment has a separate regimen and is outside this adult guide.
Isocarboxazid treats depression, often when other antidepressants have not helped adequately. It requires a specific food and medication interaction plan.
Ketamine is FDA-approved as an anesthetic. Clinicians use it off-label for some difficult-to-treat depression and other conditions. Compounded ketamine formulations have not been FDA-approved for psychiatric treatment.
L-methylfolate is sometimes added to antidepressant treatment when depression has not improved enough. Certain formulations are marketed as medical foods. That designation does not mean they have FDA approval as antidepressant drugs.
Lamotrigine is used for bipolar I maintenance treatment to delay future mood episodes and for certain seizures. It is often used in bipolar depression care, but is not an acute antimanic medicine.
Lemborexant treats adult insomnia involving difficulty falling asleep or staying asleep.
Levetiracetam treats certain seizure disorders. It is not an established treatment for bipolar disorder, and psychiatric use should have a clearly explained rationale.
Levomilnacipran treats major depression in adults. It is different from milnacipran, which is used for fibromyalgia in the United States.
Lisdexamfetamine treats ADHD and moderate to severe binge-eating disorder in adults. It is not approved for weight loss or treatment of obesity.
Lithium treats mania and helps prevent future episodes of bipolar disorder. It is also used off-label to strengthen antidepressant treatment in some people with depression.
Lofepramine treats depression in countries where it is approved. This is an international reference rather than a standard U.S. prescribing guide.
Lofexidine reduces symptoms of opioid withdrawal during a short treatment course. It does not treat opioid use disorder over the long term or prevent relapse and overdose.
Lorazepam treats anxiety and is used in clinical settings for certain seizures, procedures, or other acute conditions. The schedule and duration depend on the indication.
Oral loxapine treats schizophrenia. Inhaled Adasuve treats acute agitation associated with schizophrenia or bipolar I disorder in adults in an equipped healthcare setting.
Lumateperone treats schizophrenia, depressive episodes in bipolar I or II disorder, and is added to an antidepressant for major depression. Bipolar depression treatment may be alone or with lithium or valproate. It is not an acute antimanic treatment.
Lurasidone treats schizophrenia and depressive episodes of bipolar I disorder. In adults, bipolar depression treatment may be alone or with lithium or valproate. It is not specifically approved for acute mania.
Maprotiline is an older tetracyclic antidepressant for depression. Availability varies by country; confirm a currently supplied formulation before planning treatment.
Memantine treats symptoms of moderate to severe Alzheimer dementia. It may help cognition or daily functioning, sometimes alongside donepezil. It does not cure Alzheimer disease or establish that the underlying disease has stopped progressing.
Methadone treats opioid use disorder by reducing withdrawal and cravings. In the United States, ongoing methadone treatment for opioid use disorder is generally provided through a certified opioid treatment program. It is also used for certain pain conditions, with different prescribing arrangements.
Methylphenidate treats ADHD; certain formulations also treat narcolepsy. Approved ages and uses differ by formulation, including for skin patches.
Mianserin treats depressive illness in countries where it is supplied. It is not FDA-approved. This guide follows the reviewed UK oral labeling.
Midazolam is used for sedation during medical procedures and, in specific formulations, for seizure rescue. Nayzilam nasal spray treats prescribed seizure clusters. It is not a routine daily anxiety or sleep treatment.
Milnacipran is FDA-approved for adult fibromyalgia. It is used for depression in some other countries, but Savella is not approved for depression in the United States.
Milsaperidone treats schizophrenia in adults and acute manic or mixed episodes of bipolar I disorder. A mixed episode includes manic symptoms with depressive symptoms. The condition being treated determines the target dose and follow-up plan.
Mirtazapine treats depression. Its effects on sleep and appetite may be useful when those symptoms are part of depression, while unwanted sedation or weight gain may limit treatment.
Mixed amphetamine salts are prescribed for ADHD. Certain immediate-release formulations are also used for narcolepsy. The prescribed formulation determines the schedule and approved uses.
Moclobemide treats depression and, under some country labels, social anxiety disorder. It is not FDA-approved. This guide uses UK labeling.
Modafinil reduces excessive sleepiness associated with narcolepsy, obstructive sleep apnea, or shift-work disorder. In sleep apnea it supplements, rather than replaces, treatment of airway obstruction. Other uses are off-label.
Molindone treats schizophrenia. It may reduce hallucinations, suspicious beliefs, and disorganized thinking. Review both symptom relief and movement side effects.
In the United States, nalmefene formulations reverse known or suspected opioid overdose. This is emergency treatment and must be followed by emergency medical care.
Naloxone is an emergency medicine for a known or suspected opioid overdose. Give it when someone cannot be awakened or is not breathing normally and an opioid may be involved. Call 911 and stay with the person. Do not wait to identify the exact drug.
Naltrexone treats alcohol use disorder and helps prevent return to opioid use after detoxification. It works alongside counseling and recovery support. It does not treat acute alcohol or opioid withdrawal.
This combination supports long-term weight management in eligible adults alongside nutrition and physical activity changes. It is not approved as a stand-alone treatment for depression or substance use disorder.
Nefazodone treats depression. Its rare risk of severe liver failure and substantial medication interactions are central to deciding whether it is appropriate.
Nortriptyline treats depression. It is also used off-label for some nerve-pain and headache conditions. The target symptoms and dose may differ between these uses.
Olanzapine treats schizophrenia and bipolar I mania or mixed episodes, and can be used for maintenance. Combined with fluoxetine, it treats bipolar I depression and treatment-resistant depression under separate labeling.
This combination treats depressive episodes in bipolar I disorder and treatment-resistant depression. Treatment-resistant depression means depression that has not improved adequately with appropriate antidepressant trials. This sheet is for adults.
Lybalvi treats schizophrenia and certain phases of bipolar I disorder in adults. Samidorphan can reduce the amount of olanzapine-associated weight gain on average, but weight gain and metabolic effects can still occur.
Oxazepam treats anxiety symptoms and can be used in a supervised alcohol-withdrawal plan. It does not treat depression itself, and severe alcohol withdrawal requires urgent medical care.
Oxcarbazepine treats focal seizures. It is sometimes used off-label for mood symptoms, but evidence for bipolar treatment is limited. Confirm the specific target and how benefit will be assessed.
Paliperidone treats schizophrenia. Oral paliperidone and the monthly injection also have schizoaffective-disorder indications; the longer injection intervals have different eligibility requirements.
Paroxetine treats depression and several anxiety-related conditions, including panic disorder, social anxiety, generalized anxiety, OCD, PTSD, and PMDD, depending on the formulation. Low-dose Brisdelle is for menopausal hot flashes, not psychiatric treatment.
Perospirone is used in Japan to treat schizophrenia. It is not an FDA-approved U.S. medication. Follow the locally supplied formulation’s instructions.
Perphenazine treats schizophrenia and is also labeled for severe nausea and vomiting in adults. The dose and duration depend on the condition being treated.
Phenelzine treats depression, often after other options have not helped sufficiently. It is also used off-label for selected anxiety conditions. Food and medication precautions are essential.
This combination supports long-term weight management in eligible patients alongside nutrition and activity changes. This guide is for adults. It is not a treatment for bipolar disorder or depression.
Pimavanserin treats hallucinations and delusions associated with Parkinson disease psychosis. It is not approved for other dementia-related psychosis unless the symptoms are related to Parkinson disease.
Pimozide is used in the United States to suppress severe motor and vocal tics in Tourette disorder when standard treatment has not been sufficient. Other uses require a separate discussion.
Pipothiazine is a phenothiazine antipsychotic used internationally for psychotic disorders. Availability differs: the UK depot was withdrawn in 2015, while French Piportil information remains listed. It is not a routine U.S. treatment.
Pitolisant treats excessive daytime sleepiness or cataplexy associated with narcolepsy. Cataplexy is a brief loss of muscle strength, often triggered by emotion. This guide addresses adult treatment.
Pramipexole is approved for Parkinson disease and, in its immediate-release form, restless legs syndrome. In psychiatry, it is sometimes added to antidepressant treatment for depression that has not responded adequately. Depression treatment is off-label.
Prazosin is approved for high blood pressure. In psychiatry it is used off-label for PTSD-related nightmares. Evidence and guideline support for nightmares do not establish it as treatment for every PTSD symptom.
Pregabalin treats certain nerve-pain conditions, fibromyalgia, and focal seizures, depending on formulation. Generalized-anxiety treatment is approved in some countries and off-label in the United States.
Propranolol treats several cardiovascular conditions and helps prevent migraine or reduce tremor. Psychiatric uses such as performance anxiety or medication-related restlessness are off-label.
Protriptyline treats depression. It may feel more activating than some tricyclic antidepressants, so timing and heart-related tolerability need review.
Quazepam treats insomnia, generally for a short course. Persistent insomnia needs assessment for sleep apnea, mood symptoms, pain, and other causes, with consideration of CBT-I.
Quetiapine treats schizophrenia and bipolar disorder, including bipolar depression and mania. The extended-release formulation is also approved as an add-on for major depression. Use solely for insomnia is off-label and carries the same important risks.
Ramelteon treats insomnia characterized by difficulty falling asleep. It is not a controlled substance. Ongoing sleep problems still warrant assessment and consideration of CBT-I.
Reboxetine treats depression in countries where it is approved. It is not an approved U.S. antidepressant. This guide follows the UK formulation.
Risperidone treats schizophrenia and bipolar I manic or mixed episodes, depending on formulation. Pediatric autism-related irritability is a separate indication and is outside this adult guide.
Rivastigmine treats dementia symptoms associated with Alzheimer disease or Parkinson disease, depending on formulation and severity. It may support cognition or daily functioning for a time but does not cure the disease.
The Emsam patch treats major depression in adults. Oral selegiline formulations are used for Parkinson disease under different labeling; their dose and food rules must not be substituted for patch instructions.
In the United States, serdexmethylphenidate is supplied with dexmethylphenidate in Azstarys for ADHD. It is not prescribed as an interchangeable stand-alone methylphenidate tablet.
Sertindole treats schizophrenia in countries where it is approved, generally when another antipsychotic has not been tolerated. It is not FDA-approved and is not intended for urgent control of severe agitation.
Sertraline treats depression, OCD, panic disorder, PTSD, social anxiety disorder, and PMDD. Generalized anxiety treatment is a common off-label use. The schedule can differ for PMDD.
Sildenafil treats erectile dysfunction and, in different formulations and schedules, pulmonary arterial hypertension. It is sometimes prescribed for antidepressant-associated erectile difficulties. This guide emphasizes adult erectile-dysfunction treatment.
Sodium oxybate treats cataplexy and excessive daytime sleepiness in narcolepsy. Xywav, a different mixed-salt oxybate formulation, also has an adult idiopathic-hypersomnia indication. Instructions differ by formulation.
Solriamfetol improves wakefulness in adults with excessive daytime sleepiness from narcolepsy or obstructive sleep apnea. It does not treat airway obstruction; continue CPAP or other prescribed apnea treatment.
Sulpiride treats schizophrenia and related psychotic symptoms under UK labeling. Other country uses differ. It is not an FDA-approved U.S. medication.
Suvorexant treats adult insomnia involving difficulty falling asleep or staying asleep. It is a controlled medication and should be part of a plan that also addresses the causes of persistent insomnia.
One medicine, different schedules. Know which plan you are following before taking the first tablet.
Tasimelteon treats Non-24-Hour Sleep-Wake Disorder in adults and nighttime sleep disturbance in Smith-Magenis syndrome under age- and formulation-specific labeling. It is not a general substitute for an insomnia medicine.
Temazepam treats short-term insomnia. Persistent sleep difficulty needs reassessment and a longer-term plan, often including CBT-I.
Tetrabenazine treats chorea, the involuntary movements associated with Huntington disease. It reduces movements but does not cure Huntington disease or treat all of its thinking and mood symptoms. Other uses require a separate discussion with your provider.
Thioridazine is reserved for schizophrenia when adequate trials of other antipsychotics have not provided sufficient benefit or tolerability. Its potentially fatal heart-rhythm risk limits use.
Thiothixene treats schizophrenia. Treatment should be judged by psychotic symptoms, daily functioning, and tolerability rather than sedation alone.
Tiagabine is approved as add-on treatment for focal seizures. Psychiatric uses are off-label and require particular caution: seizures and prolonged seizure activity have occurred in people without epilepsy.
Tianeptine is prescribed for depression in some countries. It is not FDA-approved for any medical use, and FDA advises U.S. consumers not to use unlawfully marketed tianeptine preparations.
Topiramate treats certain seizures and prevents migraine. Off-label uses include selected alcohol-use or eating-related conditions. It is not an established treatment for the core mood symptoms of bipolar disorder.
Tranylcypromine treats major depression when other antidepressants have not worked adequately. It requires a clear food, medication, and blood-pressure monitoring plan.
Trazodone is approved for depression. Lower doses are often used off-label for insomnia, but a sleep dose may not adequately treat depression. The expected benefit and risks should match the reason for use.
Triazolam treats short-term insomnia. Its short action does not eliminate next-day impairment, amnesia, dependence, or withdrawal risk.
Trifluoperazine treats schizophrenia. U.S. labeling also permits limited short-term treatment of nonpsychotic anxiety when appropriate, but it is not a routine first choice for anxiety.
Trihexyphenidyl treats Parkinson-related symptoms and certain medication-induced movement effects, especially stiffness and tremor. It does not treat tardive dyskinesia and may worsen it.
Liothyronine replaces thyroid hormone in selected thyroid conditions. In psychiatry, it is sometimes added off-label to antidepressant treatment. It is not approved for weight loss and should never be used for that purpose.
Trimipramine treats depression. Its sedating effects may influence the choice of dose timing, but sleepiness alone does not establish antidepressant benefit.
Valbenazine treats tardive dyskinesia in adults and chorea associated with Huntington disease. It reduces involuntary movements; it does not cure the underlying condition.
Valproate formulations treat certain seizures; specific divalproex formulations also treat bipolar mania and prevent migraine. The reason for use determines the dose, monitoring, and reproductive precautions.
Varenicline helps adults stop smoking. It works best with a quit plan and behavioral support. The plan may use a fixed quit date, a flexible date, or gradual reduction before quitting.
Venlafaxine treats depression and, with certain extended-release formulations, generalized anxiety, social anxiety, and panic disorder. Other uses such as nerve pain are off-label.
Vilazodone treats major depression in adults. Anxiety symptoms may improve as depression improves, but it is not separately approved for every anxiety disorder.
Extended-release viloxazine treats ADHD in adults and children aged six and older. This guide is for adults. It is a nonstimulant and is not a U.S. controlled substance.
Vortioxetine treats major depression in adults. Concentration may improve with successful depression treatment, but it is not approved as a stand-alone memory or ADHD medicine.
Cobenfy treats schizophrenia in adults. Treatment may reduce hallucinations, suspiciousness, and disorganized thinking. Your provider will review both symptoms and how you are managing daily activities.
Zaleplon treats short-term insomnia involving difficulty falling asleep. Its short duration means it may not help repeated awakenings or early-morning waking.
Ziprasidone treats schizophrenia and acute manic or mixed episodes of bipolar I disorder. It is also used with lithium or valproate for bipolar maintenance. Injectable use for acute agitation has separate instructions.
Zolpidem treats insomnia. Standard formulations help with sleep onset; extended-release treatment also helps sleep maintenance. Certain low-dose sublingual formulations have separate middle-of-the-night instructions.
Zonisamide treats focal seizures. Psychiatric or weight-related uses are off-label and require a separate evidence discussion; it is not an established bipolar mood stabilizer.
Zopiclone treats short-term insomnia in countries where it is approved. It is not FDA-approved in the United States and is different from eszopiclone.
Zotepine is used in some countries for schizophrenia. It is not FDA-approved. This guide follows Japanese Lodopin information; use the locally supplied prescription and leaflet for dosing.
Zuclopenthixol treats schizophrenia and other psychotic disorders in countries where it is approved. Formulations are used for different phases of treatment. It is not FDA-approved in the United States.
Zuranolone treats postpartum depression in adults. It is a 14-day treatment course that may be used alone or with an oral antidepressant. Depression after childbirth is a medical condition that deserves treatment and practical support.
Try another name or a broader topic.
A separate collection, ready for future additions.
This collection includes topics beyond the practice’s treatment scope. Resources are educational; their inclusion does not mean a service or medication is offered here.
For general education only. This information does not replace individualized medical advice, diagnosis, or treatment. Do not start, stop, or change medication without guidance from your prescriber. For an emergency, call 911 or go to the nearest emergency department.